Literature DB >> 1473367

Ciprofloxacin plus vancomycin versus ceftazidime plus gentamicin in the treatment of pneumonia in granulocytopenic patients with or without venous catheters. Short communication.

V Krcméry1, P Fuchsberger, J Trupl, J Sufliarsky, S Spanik, I Koza, Z Kusenda, S Korec, J Svec, P Durkovic.   

Abstract

58 granulocytopenic patients with confirmed bronchopneumonia were divided retrospectively into two groups for this pilot study: group 1 included neutropenic patients with venous catheters who were treated with ciprofloxacin (CIP; 200-300 mg, i.v. b.i.d.) + vancomycin (VAN; 0.5-1 g, i.v. b.i.d.), and group 2, which included patients without venous catheters treated with ceftazidime (2 g, i.v. t.i.d.) + gentamicin (1 mg/kg, i.v. t.i.d.). Pneumonia was diagnosed clinically and radiologically in all patients; 92.3% in group 1 and 46.8% in group 2 were also microbially confirmed. Mixed infections were present in most patients. 3 of 26 patients (11.5%) in group 1 and 9 of 32 (20.1%) in group 2 did not recover while 88.5% in group 1 and 71.9% in group 2 recovered. CIP + VAN seems to be more effective in treating pneumonia in neutropenic patients, with only 1 patient in the group suffering an adverse effect compared with 5 in group 2.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473367     DOI: 10.1159/000239011

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

Review 1.  The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials.

Authors:  V Krcméry
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 2.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.